Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experience.

Autor: Frezza AM; Medical Oncology, University Campus Bio-Medico, Via Alvaro del Portillo 200, Rome 00128, Italy., Benson C; Sarcoma Unit, Royal Marsden Hospital, London, UK., Judson IR; Sarcoma Unit, Royal Marsden Hospital, London, UK., Litiere S; EORTC HQ, Brussels, Belgium., Marreaud S; EORTC HQ, Brussels, Belgium., Sleijfer S; Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Blay JY; Medical Oncology, Centre Leon Berard, Lyon, France., Dewji R; GlaxoSmithKline, Oncology, Uxbridge, UK., Fisher C; Sarcoma Unit, Royal Marsden Hospital, London, UK., van der Graaf W; Department of Medical Oncology, Radboud University Medical Center, Nijmegen, The Netherlands., Hayward L; Medical Oncology, NHS Lothians, Edinburgh, UK.
Jazyk: angličtina
Zdroj: Clinical sarcoma research [Clin Sarcoma Res] 2014 Jul 29; Vol. 4, pp. 7. Date of Electronic Publication: 2014 Jul 29 (Print Publication: 2014).
DOI: 10.1186/2045-3329-4-7
Abstrakt: Background: We retrospectively reviewed data from nine pre-treated metastatic desmoplastic small round cell tumour (DSRCT) patients who received pazopanib.
Patients and Methods: Three patients received pazopanib within the EORTC phase II 62043, three in the EORTC phase III 62072, and three in the context of UK named patient program.
Results: Nine patients were retrieved from the databases, the median age was 30 years (range: 21-47), they were all males. All had received prior chemotherapy. At the time of treatment start, 4 patients (44%) had ECOG PS 0, 4 (44%) PS 1, 1 (11%) PS 2. Best response was partial response (PR) in 2/9 (22%) patients, stable disease (SD) in 5/9 (56%) and progressive disease (PD) in 2/9 (22%) with a clinical benefit rate (PR + SD > 12 weeks) of 78%. Median PFS and OS were 9.2 (95%CI: 0-23.2) and 15.4 (95%CI: 1.5-29.3) months respectively. With a median follow-up of 20 months, 2/9 (22%) patients are still alive, all progressed. The most common toxicities included neutropenia (G1-2 45%; G3-4 11%), anaemia (G1-2 45%), fatigue (G1-2 67%), diarrhoea (G1-2 45%; G3-4 11%), nausea (G1-2 45%), hypertension (G1-2 45%) and increase in liver enzymes (G1-2 34%; G3-4 11%). Three patients (34%) required a dose reduction. One of the patients discontinued treatment because of persistent increase in total bilirubin level, one due to patient's choice.
Conclusion: In this series, pazopanib showed interesting activity in DSRCT patients who progressed after prior chemotherapy without major toxicity.
Databáze: MEDLINE
Externí odkaz: